Microwave ablation for treating small kidney and liver tumors
Retrospective and Perspective Analysis of Short, Medium and Long Term Clinical Performance of Patients Undergoing MicrowaveThermal Ablation for Treatment of Small Renal Tumors and Primary and Secondary Liver Neoplasms
IRCCS San Raffaele · NCT03981497
This study is testing whether microwave ablation can safely and effectively treat small kidney and liver tumors in patients while they continue their regular care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | IRCCS San Raffaele (other) |
| Locations | 1 site (Milan) |
| Trial ID | NCT03981497 on ClinicalTrials.gov |
What this trial studies
This observational study aims to gather data on the efficacy and safety of microwave ablation (MWA) for patients with primary and secondary liver malignancies and small renal tumors. It will evaluate the short, medium, and long-term clinical outcomes of patients undergoing MWA, comparing these results with existing literature on other treatment methods. Participants will continue their usual clinical care while data on their treatment and outcomes will be collected for analysis.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 with small primary or secondary liver tumors or small kidney tumors that are not suitable for surgical resection.
Not a fit: Patients with extensive extrahepatic or extrarenal disease, or those with non-manageable coagulopathies, are unlikely to benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the effectiveness of microwave ablation as a treatment option for patients with small renal and liver tumors.
How similar studies have performed: Other studies have shown promising results with microwave ablation for similar conditions, indicating that this approach is supported by existing evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * \> 18 years with primary or secondary liver tumors or small kidney tumors that are not candidates for surgery or cannot be radically resected by surgery alone * Primary liver cancer: up to three liver nodules ≤ 3 cm * Secondary hepatic tumours: up to nodules ≤ 3 cm provided that the objective is complete hepatic clearance Renal tumours: single or multiple (von Hippel Lindau syndrome), \< 4 cm Exclusion Criteria: * pregnant women * non-manageable coagulopathies * Extended extrahepatic or extrarenal disease * for liver ablation: presence of bilio-digestive anastomosis
Where this trial is running
Milan
- IRCCS Ospedale San Raffaele — Milan, Italy (RECRUITING)
Study contacts
- Study coordinator: Francesco De Cobelli, MD
- Email: decobelli.francesco@hsr.it
- Phone: +390226432529
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Liver Cancer, Liver Metastasis Colon Cancer, Kidney Cancer, Renal Cell Carcinoma, MWA